MovDisordV3, PascalFrancis, Corpus, bibRecord, 001D31

In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage

Identifieur interne : 001D31 ( PascalFrancis/Corpus ); précédent : 001D30; suivant : 001D32

In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage

Auteurs : Luigi Zecca ; Daniela Berg ; Thomas Arzberger ; Petra Ruprecht ; Wolf D. Rausch ; Massimo Musicco ; Davide Tampellini ; Peter Riederer ; Manfred Gerlach ; Georg Becker

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:06-0001179

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Dépistage, Fer, Exploration ultrason, Voie abord, Locus niger, Ultrason, Ferritine.

English descriptors

KwdEn :
- Ferritin, Iron, Locus niger, Medical screening, Nervous system diseases, Parkinson disease, Sonography, Surgical approach, Ultrasound.

Abstract

Early diagnosis of Parkinson's disease (PD) in nonsymptomatic patients is a key issue. An increased echogenicity of the substantia nigra (SN) was found previously in Parkinsonian patients and in a low percentage of healthy adults. These nonsymptomatic subjects also showed a reduced ¹⁸F-dopa uptake in striatum, suggesting a preclinical injury of the nigrostriatal system that could later proceed into PD. To investigate the ability of ultrasonography to detect markers of SN degeneration, such as iron deposition and neuromelanin depletion, we scanned postmortem brains from normal subjects at different ages by ultrasound and measured the echogenic area of the SN. The SN was then dissected and used for histological examinations and determination of iron, ferritin, and neuromelanin content. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. Multivariate analysis carried out considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. In PD, a typical loss of neuromelanin and increase of iron is observed in this brain area. The finding of a positive correlation between iron and ferritin levels and a negative correlation of neuromelanin content with the area of echogenicity at the SN could therefore provide an interesting basis for diagnosis and therapeutic follow-up studies in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage`
A11	`01`	`1`		`@1 ZECCA (Luigi)`
A11	`02`	`1`		`@1 BERG (Daniela)`
A11	`03`	`1`		`@1 ARZBERGER (Thomas)`
A11	`04`	`1`		`@1 RUPRECHT (Petra)`
A11	`05`	`1`		`@1 RAUSCH (Wolf D.)`
A11	`06`	`1`		`@1 MUSICCO (Massimo)`
A11	`07`	`1`		`@1 TAMPELLINI (Davide)`
A11	`08`	`1`		`@1 RIEDERER (Peter)`
A11	`09`	`1`		`@1 GERLACH (Manfred)`
A11	`10`	`1`		`@1 BECKER (Georg)`
A14	`01`			`@1 Institute of Biomedical Technologies-CNR @2 Segrate (Milano) @3 ITA @Z 1 aut. @Z 6 aut. @Z 7 aut.`
A14	`02`			`@1 Department of Medical Genetics and Hertie Institute for Clinical Brain Research @2 Tubingen @3 DEU @Z 2 aut. @Z 4 aut.`
A14	`03`			`@1 Department of Pathology, University of Würzhurg @2 Würzburg @3 DEU @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Saarland University @2 Homburg @3 DEU @Z 4 aut. @Z 10 aut.`
A14	`05`			`@1 Institute of Medical Chemistry, Veterinary University @2 Wien @3 AUT @Z 5 aut.`
A14	`06`			`@1 Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzbürg @2 Würzburg @3 DEU @Z 8 aut.`
A14	`07`			`@1 Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wurzburg @2 Würzburg @3 DEU @Z 9 aut.`
A20				`@1 1278-1285`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000135138750040`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 52 ref.`
A47	`01`	`1`		`@0 06-0001179`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Early diagnosis of Parkinson's disease (PD) in nonsymptomatic patients is a key issue. An increased echogenicity of the substantia nigra (SN) was found previously in Parkinsonian patients and in a low percentage of healthy adults. These nonsymptomatic subjects also showed a reduced ¹⁸F-dopa uptake in striatum, suggesting a preclinical injury of the nigrostriatal system that could later proceed into PD. To investigate the ability of ultrasonography to detect markers of SN degeneration, such as iron deposition and neuromelanin depletion, we scanned postmortem brains from normal subjects at different ages by ultrasound and measured the echogenic area of the SN. The SN was then dissected and used for histological examinations and determination of iron, ferritin, and neuromelanin content. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. Multivariate analysis carried out considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. In PD, a typical loss of neuromelanin and increase of iron is observed in this brain area. The finding of a positive correlation between iron and ferritin levels and a negative correlation of neuromelanin content with the area of echogenicity at the SN could therefore provide an interesting basis for diagnosis and therapeutic follow-up studies in PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B05C02D`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Dépistage @5 09`
C03	`03`	`X`	`ENG`	`@0 Medical screening @5 09`
C03	`03`	`X`	`SPA`	`@0 Descubrimiento @5 09`
C03	`04`	`X`	`FRE`	`@0 Fer @2 NC @5 10`
C03	`04`	`X`	`ENG`	`@0 Iron @2 NC @5 10`
C03	`04`	`X`	`SPA`	`@0 Hierro @2 NC @5 10`
C03	`05`	`X`	`FRE`	`@0 Exploration ultrason @5 11`
C03	`05`	`X`	`ENG`	`@0 Sonography @5 11`
C03	`05`	`X`	`SPA`	`@0 Exploración ultrasonido @5 11`
C03	`06`	`X`	`FRE`	`@0 Voie abord @5 12`
C03	`06`	`X`	`ENG`	`@0 Surgical approach @5 12`
C03	`06`	`X`	`SPA`	`@0 Vía abordaje @5 12`
C03	`07`	`X`	`FRE`	`@0 Locus niger @5 13`
C03	`07`	`X`	`ENG`	`@0 Locus niger @5 13`
C03	`07`	`X`	`SPA`	`@0 Locus níger @5 13`
C03	`08`	`X`	`FRE`	`@0 Ultrason @5 14`
C03	`08`	`X`	`ENG`	`@0 Ultrasound @5 14`
C03	`08`	`X`	`SPA`	`@0 Ultrasonido @5 14`
C03	`09`	`X`	`FRE`	`@0 Ferritine @5 15`
C03	`09`	`X`	`ENG`	`@0 Ferritin @5 15`
C03	`09`	`X`	`SPA`	`@0 Ferritina @5 15`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso central @5 38`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 002`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0001179 INIST
ET :	In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage
AU :	ZECCA (Luigi); BERG (Daniela); ARZBERGER (Thomas); RUPRECHT (Petra); RAUSCH (Wolf D.); MUSICCO (Massimo); TAMPELLINI (Davide); RIEDERER (Peter); GERLACH (Manfred); BECKER (Georg)
AF :	Institute of Biomedical Technologies-CNR/Segrate (Milano)/Italie (1 aut., 6 aut., 7 aut.); Department of Medical Genetics and Hertie Institute for Clinical Brain Research/Tubingen/Allemagne (2 aut., 4 aut.); Department of Pathology, University of Würzhurg/Würzburg/Allemagne (3 aut.); Department of Neurology, Saarland University/Homburg/Allemagne (4 aut., 10 aut.); Institute of Medical Chemistry, Veterinary University/Wien/Autriche (5 aut.); Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzbürg/Würzburg/Allemagne (8 aut.); Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wurzburg/Würzburg/Allemagne (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 10; Pp. 1278-1285; Bibl. 52 ref.
LA :	Anglais
EA :	Early diagnosis of Parkinson's disease (PD) in nonsymptomatic patients is a key issue. An increased echogenicity of the substantia nigra (SN) was found previously in Parkinsonian patients and in a low percentage of healthy adults. These nonsymptomatic subjects also showed a reduced ¹⁸F-dopa uptake in striatum, suggesting a preclinical injury of the nigrostriatal system that could later proceed into PD. To investigate the ability of ultrasonography to detect markers of SN degeneration, such as iron deposition and neuromelanin depletion, we scanned postmortem brains from normal subjects at different ages by ultrasound and measured the echogenic area of the SN. The SN was then dissected and used for histological examinations and determination of iron, ferritin, and neuromelanin content. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. Multivariate analysis carried out considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. In PD, a typical loss of neuromelanin and increase of iron is observed in this brain area. The finding of a positive correlation between iron and ferritin levels and a negative correlation of neuromelanin content with the area of echogenicity at the SN could therefore provide an interesting basis for diagnosis and therapeutic follow-up studies in PD.
CC :	002B17; 002B17G; 002B05C02D
FD :	Système nerveux pathologie; Parkinson maladie; Dépistage; Fer; Exploration ultrason; Voie abord; Locus niger; Ultrason; Ferritine
FG :	Encéphale pathologie; Système nerveux central; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Parkinson disease; Medical screening; Iron; Sonography; Surgical approach; Locus niger; Ultrasound; Ferritin
EG :	Cerebral disorder; Central nervous system; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Parkinson enfermedad; Descubrimiento; Hierro; Exploración ultrasonido; Vía abordaje; Locus níger; Ultrasonido; Ferritina
LO :	INIST-20953.354000135138750040
ID :	06-0001179

Links to Exploration step

Pascal:06-0001179

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage</title>
<author><name sortKey="Zecca, Luigi" sort="Zecca, Luigi" uniqKey="Zecca L" first="Luigi" last="Zecca">Luigi Zecca</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Genetics and Hertie Institute for Clinical Brain Research</s1>
<s2>Tubingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arzberger, Thomas" sort="Arzberger, Thomas" uniqKey="Arzberger T" first="Thomas" last="Arzberger">Thomas Arzberger</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Pathology, University of Würzhurg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ruprecht, Petra" sort="Ruprecht, Petra" uniqKey="Ruprecht P" first="Petra" last="Ruprecht">Petra Ruprecht</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Genetics and Hertie Institute for Clinical Brain Research</s1>
<s2>Tubingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Saarland University</s1>
<s2>Homburg</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rausch, Wolf D" sort="Rausch, Wolf D" uniqKey="Rausch W" first="Wolf D." last="Rausch">Wolf D. Rausch</name>
<affiliation><inist:fA14 i1="05"><s1>Institute of Medical Chemistry, Veterinary University</s1>
<s2>Wien</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Musicco, Massimo" sort="Musicco, Massimo" uniqKey="Musicco M" first="Massimo" last="Musicco">Massimo Musicco</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tampellini, Davide" sort="Tampellini, Davide" uniqKey="Tampellini D" first="Davide" last="Tampellini">Davide Tampellini</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name>
<affiliation><inist:fA14 i1="06"><s1>Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzbürg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gerlach, Manfred" sort="Gerlach, Manfred" uniqKey="Gerlach M" first="Manfred" last="Gerlach">Manfred Gerlach</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wurzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Becker, Georg" sort="Becker, Georg" uniqKey="Becker G" first="Georg" last="Becker">Georg Becker</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Saarland University</s1>
<s2>Homburg</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0001179</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0001179 INIST</idno>
<idno type="RBID">Pascal:06-0001179</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D31</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage</title>
<author><name sortKey="Zecca, Luigi" sort="Zecca, Luigi" uniqKey="Zecca L" first="Luigi" last="Zecca">Luigi Zecca</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Genetics and Hertie Institute for Clinical Brain Research</s1>
<s2>Tubingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arzberger, Thomas" sort="Arzberger, Thomas" uniqKey="Arzberger T" first="Thomas" last="Arzberger">Thomas Arzberger</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Pathology, University of Würzhurg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ruprecht, Petra" sort="Ruprecht, Petra" uniqKey="Ruprecht P" first="Petra" last="Ruprecht">Petra Ruprecht</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Genetics and Hertie Institute for Clinical Brain Research</s1>
<s2>Tubingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Saarland University</s1>
<s2>Homburg</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rausch, Wolf D" sort="Rausch, Wolf D" uniqKey="Rausch W" first="Wolf D." last="Rausch">Wolf D. Rausch</name>
<affiliation><inist:fA14 i1="05"><s1>Institute of Medical Chemistry, Veterinary University</s1>
<s2>Wien</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Musicco, Massimo" sort="Musicco, Massimo" uniqKey="Musicco M" first="Massimo" last="Musicco">Massimo Musicco</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tampellini, Davide" sort="Tampellini, Davide" uniqKey="Tampellini D" first="Davide" last="Tampellini">Davide Tampellini</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name>
<affiliation><inist:fA14 i1="06"><s1>Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzbürg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gerlach, Manfred" sort="Gerlach, Manfred" uniqKey="Gerlach M" first="Manfred" last="Gerlach">Manfred Gerlach</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wurzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Becker, Georg" sort="Becker, Georg" uniqKey="Becker G" first="Georg" last="Becker">Georg Becker</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Saarland University</s1>
<s2>Homburg</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ferritin</term>
<term>Iron</term>
<term>Locus niger</term>
<term>Medical screening</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Sonography</term>
<term>Surgical approach</term>
<term>Ultrasound</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Dépistage</term>
<term>Fer</term>
<term>Exploration ultrason</term>
<term>Voie abord</term>
<term>Locus niger</term>
<term>Ultrason</term>
<term>Ferritine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Early diagnosis of Parkinson's disease (PD) in nonsymptomatic patients is a key issue. An increased echogenicity of the substantia nigra (SN) was found previously in Parkinsonian patients and in a low percentage of healthy adults. These nonsymptomatic subjects also showed a reduced <sup>18</sup>
F-dopa uptake in striatum, suggesting a preclinical injury of the nigrostriatal system that could later proceed into PD. To investigate the ability of ultrasonography to detect markers of SN degeneration, such as iron deposition and neuromelanin depletion, we scanned postmortem brains from normal subjects at different ages by ultrasound and measured the echogenic area of the SN. The SN was then dissected and used for histological examinations and determination of iron, ferritin, and neuromelanin content. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. Multivariate analysis carried out considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. In PD, a typical loss of neuromelanin and increase of iron is observed in this brain area. The finding of a positive correlation between iron and ferritin levels and a negative correlation of neuromelanin content with the area of echogenicity at the SN could therefore provide an interesting basis for diagnosis and therapeutic follow-up studies in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ZECCA (Luigi)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BERG (Daniela)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ARZBERGER (Thomas)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RUPRECHT (Petra)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RAUSCH (Wolf D.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MUSICCO (Massimo)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TAMPELLINI (Davide)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RIEDERER (Peter)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GERLACH (Manfred)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>BECKER (Georg)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Biomedical Technologies-CNR</s1>
<s2>Segrate (Milano)</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Genetics and Hertie Institute for Clinical Brain Research</s1>
<s2>Tubingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Pathology, University of Würzhurg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Saarland University</s1>
<s2>Homburg</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Institute of Medical Chemistry, Veterinary University</s1>
<s2>Wien</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzbürg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wurzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>1278-1285</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000135138750040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>52 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0001179</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Early diagnosis of Parkinson's disease (PD) in nonsymptomatic patients is a key issue. An increased echogenicity of the substantia nigra (SN) was found previously in Parkinsonian patients and in a low percentage of healthy adults. These nonsymptomatic subjects also showed a reduced <sup>18</sup>
F-dopa uptake in striatum, suggesting a preclinical injury of the nigrostriatal system that could later proceed into PD. To investigate the ability of ultrasonography to detect markers of SN degeneration, such as iron deposition and neuromelanin depletion, we scanned postmortem brains from normal subjects at different ages by ultrasound and measured the echogenic area of the SN. The SN was then dissected and used for histological examinations and determination of iron, ferritin, and neuromelanin content. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. Multivariate analysis carried out considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. In PD, a typical loss of neuromelanin and increase of iron is observed in this brain area. The finding of a positive correlation between iron and ferritin levels and a negative correlation of neuromelanin content with the area of echogenicity at the SN could therefore provide an interesting basis for diagnosis and therapeutic follow-up studies in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B05C02D</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Fer</s0>
<s2>NC</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Iron</s0>
<s2>NC</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hierro</s0>
<s2>NC</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Exploration ultrason</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Sonography</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Exploración ultrasonido</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Voie abord</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Surgical approach</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vía abordaje</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Ultrason</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Ultrasound</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ultrasonido</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Ferritine</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Ferritin</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ferritina</s0>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>002</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0001179 INIST</NO>
<ET>In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage</ET>
<AU>ZECCA (Luigi); BERG (Daniela); ARZBERGER (Thomas); RUPRECHT (Petra); RAUSCH (Wolf D.); MUSICCO (Massimo); TAMPELLINI (Davide); RIEDERER (Peter); GERLACH (Manfred); BECKER (Georg)</AU>
<AF>Institute of Biomedical Technologies-CNR/Segrate (Milano)/Italie (1 aut., 6 aut., 7 aut.); Department of Medical Genetics and Hertie Institute for Clinical Brain Research/Tubingen/Allemagne (2 aut., 4 aut.); Department of Pathology, University of Würzhurg/Würzburg/Allemagne (3 aut.); Department of Neurology, Saarland University/Homburg/Allemagne (4 aut., 10 aut.); Institute of Medical Chemistry, Veterinary University/Wien/Autriche (5 aut.); Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzbürg/Würzburg/Allemagne (8 aut.); Department of Child and Adolescent Psychiatry and Psychotherapy, University of Wurzburg/Würzburg/Allemagne (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 10; Pp. 1278-1285; Bibl. 52 ref.</SO>
<LA>Anglais</LA>
<EA>Early diagnosis of Parkinson's disease (PD) in nonsymptomatic patients is a key issue. An increased echogenicity of the substantia nigra (SN) was found previously in Parkinsonian patients and in a low percentage of healthy adults. These nonsymptomatic subjects also showed a reduced <sup>18</sup>
F-dopa uptake in striatum, suggesting a preclinical injury of the nigrostriatal system that could later proceed into PD. To investigate the ability of ultrasonography to detect markers of SN degeneration, such as iron deposition and neuromelanin depletion, we scanned postmortem brains from normal subjects at different ages by ultrasound and measured the echogenic area of the SN. The SN was then dissected and used for histological examinations and determination of iron, ferritin, and neuromelanin content. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. Multivariate analysis carried out considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. In PD, a typical loss of neuromelanin and increase of iron is observed in this brain area. The finding of a positive correlation between iron and ferritin levels and a negative correlation of neuromelanin content with the area of echogenicity at the SN could therefore provide an interesting basis for diagnosis and therapeutic follow-up studies in PD.</EA>
<CC>002B17; 002B17G; 002B05C02D</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Dépistage; Fer; Exploration ultrason; Voie abord; Locus niger; Ultrason; Ferritine</FD>
<FG>Encéphale pathologie; Système nerveux central; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Parkinson disease; Medical screening; Iron; Sonography; Surgical approach; Locus niger; Ultrasound; Ferritin</ED>
<EG>Cerebral disorder; Central nervous system; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Descubrimiento; Hierro; Exploración ultrasonido; Vía abordaje; Locus níger; Ultrasonido; Ferritina</SD>
<LO>INIST-20953.354000135138750040</LO>
<ID>06-0001179</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D31 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001D31 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0001179
   |texte=   In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage

In vivo detection of iron and neuromelanin by transcranial sonography : A new approach for early detection of substantia nigra damage

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri